Hello Friends! As always, I must remind you to consult with your own financial advisors before taking any action based on anything written here. I hope that my comments DO however, give you something to talk about with them! I do not own any shares of CollaGenex Pharmaceutical (CGPI), but it does look like an interesting selection today!
CGPI currently is trading at $10.45 up $1.19 or 12.85% on the day. According to money.cnn.com, CGPI "...is a pharmaceutical company focused on providing innovative medical therapies for the treatment of periodontitis and other pathologies characterized by the progressive degradation of the body's connective tissue."
On October 28, 2003, CGPI reported results for their fiscal third quarter ended September 30, 2003. Total revenues increased 24% to $13.9 million compared to $11.2 million last year.
Net income was $1.5 million or $.13/share compared to net income of $356,000 or $.03/share last year.
Morningstar.com shows growth in revenue from $3 million in 1998, $16 million in 1999, $24 million in 2000, $35 million in 2001, $45 million in 2002, and extrapolating the current quarter would get us over $50 million in revenue in 2003.
Earnings/share have improved from a loss of ($1.35) in 1998 to a positive $.27/share in the trailing twelve months. Free cash flow has also improved recently from ($9) million in 2000, ($8) million in 2001, $4 million in 2002 and $8 million in trailing twelve months.
The balance sheet looks terrific with $11.5 million in cash per Morningstar, more than enough to cover both the current liabilities of $6.5 million and the long-term liabilities of $0.3 million combined. In addition, CGPI has $5.4 million of other current assets.
Looking at Yahoo.com, we find that shares are actually up because of a settlement of a patent dispute against West-ward Pharmaceutical Corporation. This is just ANOTHER piece of good news for this stock. Looking at "Yahoo statistics" on CGPI, we find that this is indeed a small cap stock with a market cap of $118.32 million. The trailing p/e is at 30.0 but the forward p/e (2004), is at 16.54 based on estimates. No PEG ratio noted as company just turned profitable, and Price/Sales not too bad at 2.11.
Currently there are 11.50 million shares outstanding and 7.50 million of them that float. There are 921,000 shares out short representing 3.87 days of trading. With the small float of this stock, we may be witnessing a short 'squeeze'...days short were as of 10/8/03.
This is a SMALL company that I do like a lot. If we had room in our portfolio, I might purchase some shares. You might wish to discuss this with your own investment advisor to see if it is suitable for your needs. Thanks again for stopping by! If you have any questions or comments, please feel free to post them here or email me at bobsadviceforstocks@lycos.com .
Bob